OBJECTIVE: To determine the influence of ethnicity and sociodemographic factors on disease characteristics of the Canadian pediatric lupus population. METHODS: Childhood-onset systemic lupus erythematosus (SLE) patients at 4 pediatric centers in Halifax, Montreal, Toronto, and Vancouver were consecutively recruited. Sociodemographics and disease data were collected. Patients were categorized by their primary self-selected ethnicity, and exploratory cluster analyses were examined for disease expression by ethnicity. RESULTS: We enrolled 213 childhood-onset SLE patients, and ethnicity data were available for 206 patients: white (31%), Asian (30%), South Asian (15%), black (10%), Latino/Hispanic (4%), Aboriginal (4%), and Arab/Middle Eastern (3%). The frequency of clinical classification criteria (malar rash, arthritis, serositis, and renal disease) and autoantibodies significantly differed among ethnicities. Medications were prescribed equally across ethnicities: 76% were taking prednisone, 86% antimalarials, and 56% required additional immunosuppressants. Cluster analysis partitioned into 3 main groups: mild (n = 50), moderate (n = 82), and severe (n = 68) disease clusters. Only 20% of white patients were in the severe cluster compared to 51% of Asian and 41% of black patients (P = 0.03). However, disease activity indices and damage scores were similar across ethnicities. CONCLUSION: Canadian childhood-onset SLE patients reflect our multiethnic population, with differences in disease manifestations, autoantibody profiles, and severity of disease expression by ethnicity.
OBJECTIVE: To determine the influence of ethnicity and sociodemographic factors on disease characteristics of the Canadian pediatric lupus population. METHODS: Childhood-onset systemic lupus erythematosus (SLE) patients at 4 pediatric centers in Halifax, Montreal, Toronto, and Vancouver were consecutively recruited. Sociodemographics and disease data were collected. Patients were categorized by their primary self-selected ethnicity, and exploratory cluster analyses were examined for disease expression by ethnicity. RESULTS: We enrolled 213 childhood-onset SLEpatients, and ethnicity data were available for 206 patients: white (31%), Asian (30%), South Asian (15%), black (10%), Latino/Hispanic (4%), Aboriginal (4%), and Arab/Middle Eastern (3%). The frequency of clinical classification criteria (malar rash, arthritis, serositis, and renal disease) and autoantibodies significantly differed among ethnicities. Medications were prescribed equally across ethnicities: 76% were taking prednisone, 86% antimalarials, and 56% required additional immunosuppressants. Cluster analysis partitioned into 3 main groups: mild (n = 50), moderate (n = 82), and severe (n = 68) disease clusters. Only 20% of white patients were in the severe cluster compared to 51% of Asian and 41% of black patients (P = 0.03). However, disease activity indices and damage scores were similar across ethnicities. CONCLUSION: Canadian childhood-onset SLEpatients reflect our multiethnic population, with differences in disease manifestations, autoantibody profiles, and severity of disease expression by ethnicity.
Authors: Paivi M Miettunen; Oliva Ortiz-Alvarez; Ross E Petty; Rolando Cimaz; Peter N Malleson; David A Cabral; Stephanie Ensworth; Lori B Tucker Journal: J Rheumatol Date: 2004-08 Impact factor: 4.666
Authors: Wilmer L Sibbitt; John R Brandt; Courtney R Johnson; Marcos E Maldonado; Samir R Patel; Corey C Ford; Arthur D Bankhurst; William M Brooks Journal: J Rheumatol Date: 2002-07 Impact factor: 4.666
Authors: Bernardo A Pons-Estel; Luis J Catoggio; Mario H Cardiel; Enrique R Soriano; Silvana Gentiletti; Antonio R Villa; Isaac Abadi; Francisco Caeiro; Alejandro Alvarellos; Donato Alarcón-Segovia Journal: Medicine (Baltimore) Date: 2004-01 Impact factor: 1.889
Authors: Fernanda J Fiorot; Aline G Islabão; Rosa M Pereira; Maria T Terreri; Claudia Saad-Magalhães; Glaucia V Novak; Beatriz C Molinari; Ana P Sakamoto; Nadia E Aikawa; Lucia M Campos; Octavio A Peracchi; Simone Appenzeller; Virgínia P Ferriani; Marco F Silva; Adriana R Fonseca; Flávio R Sztajnbok; Luciana B Paim; Melissa M Fraga; Eunice M Okuda; Blanca E Bica; Evaldo G Sena; Ana J Moraes; Ana M Rolim; Paulo F Spelling; Iloite M Scheibel; André S Cavalcanti; Erica N Matos; Teresa C Robazzi; Luciano J Guimarães; Flávia P Santos; Valeria C Ramos; Magda Carneiro-Sampaio; Eloisa Bonfá; Clovis A Silva Journal: Clin Rheumatol Date: 2019-06-13 Impact factor: 2.980
Authors: Deborah M Levy; Christine A Peschken; Lori B Tucker; Gaëlle Chédeville; Adam M Huber; Janet E Pope; Earl D Silverman Journal: Arthritis Care Res (Hoboken) Date: 2014-12 Impact factor: 4.794
Authors: Kimberly DeQuattro; Laura Trupin; Louise B Murphy; Stephanie Rush; Lindsey A Criswell; Cristina M Lanata; Maria Dall'Era; Patricia Katz; Jinoos Yazdany Journal: Arthritis Care Res (Hoboken) Date: 2022-04-20 Impact factor: 5.178
Authors: D James Haddon; Vivian K Diep; Jordan V Price; Cindy Limb; Paul J Utz; Imelda Balboni Journal: Arthritis Res Ther Date: 2015-06-17 Impact factor: 5.156
Authors: N Groot; D Shaikhani; Y K O Teng; K de Leeuw; M Bijl; R J E M Dolhain; E Zirkzee; R Fritsch-Stork; I E M Bultink; S Kamphuis Journal: Arthritis Rheumatol Date: 2019-02 Impact factor: 10.995